JAZZ Looks 64.2% Overvalued on GF Value™ Amid $1.1B Note Offering

gurufocus.com · 2026-08-27

On August 27, 2026, Jazz Pharmaceuticals (NASDAQ: JAZZ) announced the pricing of $1.1 billion in exchangeable senior notes bearing a 1.875% interest rate, matur

Read the full story at gurufocus.com →